CD8A and neoplasm: TAK-500 [254], a STING agonist, activates CCR2+ myeloid cells in the tumor microenvironment and converts immune suppressive “cold tumor” into “hot tumor” characterized by CD8+ T cell proliferation and activation [254,255].